International Multicentric Study ARON-1 on Immuno-Combination Treatments for Metastatic Renal Cell Carcinoma

What this Trial Is About

Researchers are conducting the ARON-1 Study, an international and multicenter observational study, to gather worldwide experiences on using immuno-combination therapies for patients with metastatic renal cell carcinoma RCC. This research includes two supplementary studies focused on analyzing genomic signatures from tumor samples and characterizing immune cell populations in patients treated with first-line immuno-combinations for advanced RCC. The treatments being evaluated include combinations such as pembrolizumab plus axitinib, nivolumab plus ipilimumab, nivolumab plus cabozantinib, pembrolizumab plus lenvatinib, avelumab plus axitinib, and atezolizumab plus bevacizumab. These therapies are studied as first-line treatments for metastatic RCC, allowing researchers to compare outcomes across different immuno-combination regimens. Participants provide data retrospectively, with researchers reviewing clinical outcomes such as progression-free survival, overall survival, and overall response rate. Additional analyses focus on treatment efficacy in elderly patients, patients with bone or brain metastases, and those with non-clear cell RCC. The study also examines the prognostic impact of smoking and obesity. Data collection continues until September 2027, with no direct intervention or active treatment administration during the study period.

International Multicentric Study ARON-1